Excellent Surgical Response Noted at the Higher, 100 mg/m 2 Dose  Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month Period, Up to 17 Doses LAWRENCEVILLE, N.J. , May 29, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:

Phase III OPTIMA Study on Track for Interim Data Analysis in July Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J , May 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug development company, today announced financial results for the three

LAWRENCEVILLE, N.J. , May 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the first quarter ended March 31, 2020 and provide an update on its development programs for ThermoDox ® , its

Added Capital Strengthens Balance Sheet, Assures Cash Through Major Phase III OPTIMA Study Data Readout Events Sale of an Additional $2.0 Million of NOL’s Expected in the 4 th Quarter of 2020 LAWRENCEVILLE, N.J. , April 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology

Independent Data Monitoring Committee is Expected to Meet in July 2020  to Evaluate Overall Survival Data LAWRENCEVILLE, N.J. , April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, announces that the prescribed minimum number of events of 158

Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population Synthetic Randomization Provides Means to Evaluate Strategies to Accelerate GEN-1 Clinical Program for Newly Diagnosed Stage III/IV Ovarian Cancer LAWRENCEVILLE, N.J. , March 26, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation

Enters 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline Conference Call Begins at 11:00 a.m. Eastern Time on Thursday March 26, 2020 LAWRENCEVILLE, N.J. , March 25, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug development company, today announced

Approval Adds 10 Years of Market Exclusivity Following Marketing Authorization in Europe LAWRENCEVILLE, N.J. , March 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced the European Medicines Agency (EMA) Committee for Orphan

  Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer  and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J. , March 19, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss

  R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to Proceed with Phase II Portion of the OVATION 2 Study After All Phase I Patients Have Completed Their Full Treatment Regimen (up to